asal spray of mometasone 0.05% effects on olfactory improvement in COVID-19
Phase 2
Recruiting
- Conditions
- Anosmia.AnosmiaR43.0
- Registration Number
- IRCT20190804044429N6
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR and
had an olfactory dysfunction ( reduced or loss of sense of smell) for two weeks
Exclusion Criteria
Pregnancy and lactation
History of olfactory dysfunction
Taking drugs that affect the olfactory disorders
Corticosteroids chronic use
Nasal anatomic dysfunction
Existence of dry ducts or nasal bleeding
Existence of herpetic lesion
Dissatisfaction with participating in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Olfactory symptoms improvement. Timepoint: before intervention and one month later. Method of measurement: Pennsylvania score and Visual Analogue Scale.;Safety of mometasone nasal spray. Timepoint: weekly during the study. Method of measurement: patient tolerability.
- Secondary Outcome Measures
Name Time Method Olfactory symptoms improvement duration. Timepoint: End of treatment. Method of measurement: Patient interview.;Determination of effective patient factors on olfactory dysfunction. Timepoint: study period. Method of measurement: patient interview.